NCT04130516 - Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

October 21, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 15, 2027

Conditions

Solid Tumor, Adult

Interventions

DRUG

LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER

BIOLOGICAL

Pembrolizumab - anti-PD-1 antibody

pembrolizumab- anti-PD-1 antibody

Trial Locations (10)

10032

RECRUITING

Columbia University Herbert Irving Comprehensive Cancer Center, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

19106

RECRUITING

University of Pennsylvania, Philadelphia

19107

RECRUITING

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia

77030

RECRUITING

MD Anderson Cancer Center, Houston

78229

RECRUITING

The START Center for Cancer Care, San Antonio

87106

RECRUITING

University of New Mexico Comprehensive Cancer Center, Albuquerque

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

06519

RECRUITING

Yale Cancer Center, New Haven

02114

RECRUITING

Massachusetts General Hospital, Boston